110
Z. Liu and Y. Liu
derivative loaded in graphene oxide nanosheets for chemo-photothermal synergetic cancer
therapy. J Mat Chem B 8(18):4046–4055
70. Hu Y, Niemeyer CM (2020) Designer DNA-silica/carbon nanotube nanocomposites for
traceable and targeted drug delivery. J Mater Chem B 8(11):2250–2255
71. Alshaer W, Hillaireau H, Vergnaud J, Mura S, Deloménie C, Sauvage F, Ismail S, Fattal E
(2018) Aptamer-guided siRNA-loaded nanomedicines for systemic gene silencing in CD-44
expressing murine triple-negative breast cancer model. J Contr Rel Offic J Contr Rel Soc
271:98–106
72. Seleci DA, Seleci M, Jochums A, Walter JG, Stahl F, Scheper T (2016) Aptamer mediated
niosomal drug delivery. RSC Adv 6(91):87910–87918
73. Huang X, Wan J, Leng D, Zhang Y, Yang S (2020) Dual-targeting nanomicelles with CD133
and CD44 aptamers for enhanced delivery of gefitinib to two populations of lung cancerinitiating cells. Exp Ther Med 19(1):192–204
74. Ma Q, Qian W, Tao W, Zhou Y, Xue B (2019) Delivery of curcumin nanoliposomes using
surface modified with CD133 aptamers for prostate cancer. Drug Des Devel Ther 13:4021–
4033
75. Liu Z, Zhao H, He L, Yao Y, Zhou Y, Wu J, Liu J, Ding J (2015) Aptamer density dependent
cellular uptake of lipid-capped polymer nanoparticles for polyvalent targeted delivery of
vinorelbine to cancer cells. RSC Adv 5(22):16931–16939
76. Xing H, Li J, Xu W, Hwang K, Wu P, Yin Q, Li Z, Cheng J, Lu Y (2016) The effects of
spacer length and composition on aptamer-mediated cell-specific targeting with nanoscale
PEGylated liposomal doxorubicin. ChemBioChem 17(12):1111–1117
77. Li L, Hou J, Liu X, Guo Y, Wu Y, Zhang L, Yang Z (2014) Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant
melanomas. Biomaterials 35(12):3840–3850
78. Luo C, Hu X, Peng R, Huang H, Liu Q, Tan W (2019) Biomimetic carriers based on giant
membrane vesicles for targeted drug delivery and photodynamic/photothermal synergistic
therapy. ACS Appl Mater Inter 11(47):43811–43819
79. Namee NM (1870) O’Driscoll L (2018) Extracellular vesicles and anti-cancer drug resistance.
Biochim Biophys Acta Rev Cancer 2:123–136
80. Wang Y, Chen X, Tian B, Liu J, Yang L, Zeng L, Chen T, Hong A, Wang X (2017) Nucleolintargeted extracellular vesicles as a versatile platform for biologics delivery to breast cancer.
Theranostics 7(5):1360–1372
81. Pi F, Binzel DW, Lee TJ, Li Z, Sun M, Rychahou P, Li H, Haque F, Wang S, Croce CM,
Guo B, Evers BM, Guo P (2018) Nanoparticle orientation to control RNA loading and ligand
display on extracellular vesicles for cancer regression. Nat Nanotechnol 13(1):82–89
82. Luo ZW, Li FX, Liu YW, Rao SS, Yin H, Huang J, Chen CY, Hu Y, Zhang Y, Tan YJ, Yuan LQ,
Chen TH, Liu HM, Cao J, Liu ZZ, Wang ZX, Xie H (2019) Aptamer-functionalized exosomes
from bone marrow stromal cells target bone to promote bone regeneration. Nanoscale
11(43):20884–20892
83. Zou J, Shi M, Liu X, Jin C, Xing X, Qiu L, Tan W (2019) Aptamer-functionalized exosomes:
elucidating the cellular uptake mechanism and the potential for cancer-targeted chemotherapy.
Anal Chem 91(3):2425–2430
84. Jiao J, Zou Q, Zou MH, Guo RM, Zhu S, Zhang Y (2016) Aptamer-modified PLGA
nanoparticle delivery of triplex forming oligonucleotide for targeted prostate cancer therapy.
Neoplasma 63(4):569–575
85. Bahreyni A, Alibolandi M, Ramezani M, Sarafan Sadeghi A, Abnous K, Taghdisi SM (2019)
A novel MUC1 aptamer-modified PLGA-epirubicin-PβAE-antimir-21 nanocomplex platform
for targeted co-delivery of anticancer agents in vitro and in vivo. Colloids Surf B Biointer
175:231–238
86. Fang Y, Lin S, Yang F, Situ J, Lin S, Luo Y (2020) Aptamer-conjugated multifunctional polymeric nanoparticles as cancer-targeted, MRI-ultrasensitive drug delivery systems for treatment
of castration-resistant prostate cancer. Biomed Res Int 2020:9186583
Z. Liu and Y. Liu
derivative loaded in graphene oxide nanosheets for chemo-photothermal synergetic cancer
therapy. J Mat Chem B 8(18):4046–4055
70. Hu Y, Niemeyer CM (2020) Designer DNA-silica/carbon nanotube nanocomposites for
traceable and targeted drug delivery. J Mater Chem B 8(11):2250–2255
71. Alshaer W, Hillaireau H, Vergnaud J, Mura S, Deloménie C, Sauvage F, Ismail S, Fattal E
(2018) Aptamer-guided siRNA-loaded nanomedicines for systemic gene silencing in CD-44
expressing murine triple-negative breast cancer model. J Contr Rel Offic J Contr Rel Soc
271:98–106
72. Seleci DA, Seleci M, Jochums A, Walter JG, Stahl F, Scheper T (2016) Aptamer mediated
niosomal drug delivery. RSC Adv 6(91):87910–87918
73. Huang X, Wan J, Leng D, Zhang Y, Yang S (2020) Dual-targeting nanomicelles with CD133
and CD44 aptamers for enhanced delivery of gefitinib to two populations of lung cancerinitiating cells. Exp Ther Med 19(1):192–204
74. Ma Q, Qian W, Tao W, Zhou Y, Xue B (2019) Delivery of curcumin nanoliposomes using
surface modified with CD133 aptamers for prostate cancer. Drug Des Devel Ther 13:4021–
4033
75. Liu Z, Zhao H, He L, Yao Y, Zhou Y, Wu J, Liu J, Ding J (2015) Aptamer density dependent
cellular uptake of lipid-capped polymer nanoparticles for polyvalent targeted delivery of
vinorelbine to cancer cells. RSC Adv 5(22):16931–16939
76. Xing H, Li J, Xu W, Hwang K, Wu P, Yin Q, Li Z, Cheng J, Lu Y (2016) The effects of
spacer length and composition on aptamer-mediated cell-specific targeting with nanoscale
PEGylated liposomal doxorubicin. ChemBioChem 17(12):1111–1117
77. Li L, Hou J, Liu X, Guo Y, Wu Y, Zhang L, Yang Z (2014) Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant
melanomas. Biomaterials 35(12):3840–3850
78. Luo C, Hu X, Peng R, Huang H, Liu Q, Tan W (2019) Biomimetic carriers based on giant
membrane vesicles for targeted drug delivery and photodynamic/photothermal synergistic
therapy. ACS Appl Mater Inter 11(47):43811–43819
79. Namee NM (1870) O’Driscoll L (2018) Extracellular vesicles and anti-cancer drug resistance.
Biochim Biophys Acta Rev Cancer 2:123–136
80. Wang Y, Chen X, Tian B, Liu J, Yang L, Zeng L, Chen T, Hong A, Wang X (2017) Nucleolintargeted extracellular vesicles as a versatile platform for biologics delivery to breast cancer.
Theranostics 7(5):1360–1372
81. Pi F, Binzel DW, Lee TJ, Li Z, Sun M, Rychahou P, Li H, Haque F, Wang S, Croce CM,
Guo B, Evers BM, Guo P (2018) Nanoparticle orientation to control RNA loading and ligand
display on extracellular vesicles for cancer regression. Nat Nanotechnol 13(1):82–89
82. Luo ZW, Li FX, Liu YW, Rao SS, Yin H, Huang J, Chen CY, Hu Y, Zhang Y, Tan YJ, Yuan LQ,
Chen TH, Liu HM, Cao J, Liu ZZ, Wang ZX, Xie H (2019) Aptamer-functionalized exosomes
from bone marrow stromal cells target bone to promote bone regeneration. Nanoscale
11(43):20884–20892
83. Zou J, Shi M, Liu X, Jin C, Xing X, Qiu L, Tan W (2019) Aptamer-functionalized exosomes:
elucidating the cellular uptake mechanism and the potential for cancer-targeted chemotherapy.
Anal Chem 91(3):2425–2430
84. Jiao J, Zou Q, Zou MH, Guo RM, Zhu S, Zhang Y (2016) Aptamer-modified PLGA
nanoparticle delivery of triplex forming oligonucleotide for targeted prostate cancer therapy.
Neoplasma 63(4):569–575
85. Bahreyni A, Alibolandi M, Ramezani M, Sarafan Sadeghi A, Abnous K, Taghdisi SM (2019)
A novel MUC1 aptamer-modified PLGA-epirubicin-PβAE-antimir-21 nanocomplex platform
for targeted co-delivery of anticancer agents in vitro and in vivo. Colloids Surf B Biointer
175:231–238
86. Fang Y, Lin S, Yang F, Situ J, Lin S, Luo Y (2020) Aptamer-conjugated multifunctional polymeric nanoparticles as cancer-targeted, MRI-ultrasensitive drug delivery systems for treatment
of castration-resistant prostate cancer. Biomed Res Int 2020:9186583